@article{oai:u-ryukyu.repo.nii.ac.jp:02015950,
 author = {佐久川, 廣 and 仲宗根, 啓樹 and 仲吉, 朝史 and 川上, 祐子 and 諸喜田, 林 and 新村, 政昇 and 照屋, 寛 and 前原, 信人 and 金城, 渚 and 外間, 昭 and 大城, 淳一 and 金城, 福則 and 斎藤, 厚 and 山城, 章裕 and 上地, 博之 and 親泊, 康朝 and 石原, 昌清 and 嘉手納, 啓三 and 大湾, 朝二 and 宮平, 守博 and 池間, 稔 and 仲吉, 朝邦 and 与儀, 裕 and 小波津, 寛 and 中村, 博 and 城間, 健治 and 比嘉, 昌文 and 平山, 良克 and 上原, 剛 and Sakugawa, Hiroshi and Nakasone, Hiroki and Nakayoshi, Tomofumi and Kawakami, Yuko and Shokita, Hayashi and Niimura, Seisho and Teruya, Hiroshi and Maehara, Nobuto and Kinjo, Nagisa and Hokama, Akira and Ohshiro, Junichi and Kinjo, Fukunori and Saito, Atsushi and Yamashiro, Akihiro and Uechi, Hiroyuki and Oyadomari, Yasutomo and Ishihara, Masakiyo and Kadena, Keizo and Ohwan, Choji and Miyahira, Morihiro and Ikema, Minoru and Nakayoshi, Tomokuni and Yogi, Yutaka and Kohatsu, Hiroshi and Nakamura, Hiroshi and Shiroma, Kenji and Higa, Masafumi and Hirayama, Yoshikatsu and Uehara, Takeshi},
 issue = {2},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 month = {},
 note = {Five different dosage regimens of recombinant interferon ($ \gamma $IFN) alfa-2 b were compared in patients with chronic hepatitis C. Ninety-four patients were assigned to one of five groups: group 1, 2 and 3 were given 3, 6 and 10 million units (MU) , respectively, of $ \gamma $IFN alfa-2b daily for 2 weeks, followed by thrice weekly for 22 weeks (total dose: 240, 480 and 800 MU) , respectively. Group 4 and 5 were given 10 MU of $ \gamma $IFN alfa-2b daily for 2 weeks, followed by 10 MU thrice weekly for 12 weeks (group 4) or 6 MU thrice weekly for 22 weeks (group 5), with a total dose of480 and 536 MU, respectively. Sustained response to $ \gamma $IFN was seen in 7.7% (1/13) of patients in group 1. The rate was significantly lower than that of either group 2 or 3 (p<0. 05 in each comparison). There was no difference in the sustained response rate between group 2 and 3 (38.0%vs 44.0%). Comparison of the efficacy of group 4 or 5 with those of the other groups was not appropriate because of the small number of patients assigned in group 4 or 5. When the sustained response rate of patients infected with genotype 1b, which was known to be resistent to IFN treatment, is compared between group 2 and 3, higher response rate was seen in group 3 (26.3% in group 2 vs 42.1% in group 3), although not significantly., 論文},
 pages = {71--74},
 title = {[原著］C型慢性肝炎におけるリコンビナント,インターフェロン$ \alpha $-2bの用量別の治療効果},
 volume = {16},
 year = {1996}
}